Strategic Platform Acrivon’s Generative Phosphoproteomics AP3 platform enables precision patient selection across oncology targets, creating compelling collaboration angles for co-development or in-licensing deals with upside in hard-to-target cancers.

Ras Targeting Recent focus on stapled peptide therapies for RAS-driven cancers, including a KRAS G12C candidate, presents a clear opportunity for partnerships around difficult mutations with high unmet need.

Clinical-Stage Momentum As a clinical-stage company with external funding and ongoing presentations at AACR and TD Cowen conferences, there is opportunities to engage in early deal theater, advisory collaborations, or milestone-driven partnerships.

Biomarker Leadership Internal biomarker discovery capabilities via the Lund, Sweden unit can support companion diagnostics development, enabling BD teams to offer integrated asset-optimizing strategies to potential partners.

Strategic Fit Broader applicability across drug classes and modalities, combined with a relatively lean team and strong funding, positions Acrivon as an attractive partner for asset-centered collaborations, especially with mid-to-large biotech and specialty pharma seeking accelerated trials.